Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTS64P2)

• DTT Name: Androgen receptor (AR) DTT Info
• Gene Name: AR

Molecule-Related Drug & Molecule List

19 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARN-509	DMT81LZ	Acute myeloid leukaemia	2A60	Approved	[1]
Bicalutamide	DMZMSPF	Prostate cancer	2C82.0	Approved	[2]
Clascoterone	DMPGR1E	Acne vulgaris	ED80	Approved	[3]
Cyproterone	DMQXLD2	Prostate cancer	2C82.0	Approved	[4]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[5]
Dromostanolone	DMF2JDG	Aplastic anemia	3A70	Approved	[6]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[7]
Ethylestrenol	DM20VMW	Testosterone deficiency	5A81.1	Approved	[8]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[9]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[10]
Fluoxymesterone	DMUHCF1	Breast cancer	2C60-2C65	Approved	[11]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[12]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[13]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[14]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[15]
Oxandrolone	DMU9MYJ	Alcoholic hepatitis	DB94.1	Approved	[16]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[17]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[18]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[19]

23 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HC-1119	DMB06MU	Prostate cancer	2C82.0	Phase 3	[20]
ZANOTERONE	DM9HUYP	Prostate hyperplasia	GA90	Phase 3	[21]
ASC-J9	DMDQS4W	End-stage renal disease	GB61.5	Phase 2	[22]
ASCJ-9	DMMBVCJ	Acne vulgaris	ED80	Phase 2	[23]
AZD5312	DMJ8V3K	Prostate cancer	2C82.0	Phase 2	[24]
MK-0773	DM2CJB4	Osteoporosis	FB83.0	Phase 2	[25]
Testogen TDS	DMMK6IT	Hypogonadism	5A61.0	Phase 2	[26]
TOK-001	DMVJWPR	Prostate cancer	2C82.0	Phase 2	[27]
APC-100	DM71I53	Prostate cancer	2C82.0	Phase 1/2	[28]
ARV-110	DMYCID5	Prostate cancer	2C82.0	Phase 1/2	[29]
ARV-471	DM276Y8	Breast cancer	2C60-2C65	Phase 1/2	[30]
ARV-766	DM8IUV1	Prostate cancer	2C82.0	Phase 1/2	[31]
ONC1-13B	DM2DHJS	Prostate cancer	2C82.0	Phase 1/2	[32]
AC0176	DM9WJFX	Prostate cancer	2C82.0	Phase 1	[33]
AZD-3514	DMC1BXV	Prostate cancer	2C82.0	Phase 1	[34]
CC-94676	DM4581B	Invasive prostate cancer	2C82	Phase 1	[35]
Drug 2881078	DMWXQC9	Heart failure	BD10-BD13	Phase 1	[36]
DT-200	DMYFOJQ	Duchenne dystrophy	8C70	Phase 1	[37]
EPI-7386	DMUFN29	Prostate cancer	2C82.0	Phase 1	[38]
PS-178990	DM2594H	Muscle atrophy	FB32.Y	Phase 1	[39]
RAD-140	DMNVDI2	Breast cancer	2C60-2C65	Phase 1	[40]
TAS3681	DMFG6ML	Prostate cancer	2C82.0	Phase 1	[41]
TESTOSTERONE BUCICLATE	DM3DUHL	Contraception	QA21	Phase 1	[26]

11 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GW-275919	DMOIL29	Pain	MG30-MG3Z	Discontinued in Phase 2	[42]
HE-2000	DMWH4CY	Cystic fibrosis	CA25	Discontinued in Phase 2	[43]
NP-619	DM50PZH	Alopecia	ED70	Discontinued in Phase 2	[44]
Testosterone glucoside	DM5O6HM	Hypogonadism	5A61.0	Discontinued in Phase 2	[26]
GSK2849466	DMM7Q3L	Heart failure	BD10-BD13	Discontinued in Phase 1	[45]
LGD2941	DM9LEGU	Osteoporosis	FB83.0	Discontinued in Phase 1	[46]
MX-4509	DMC4RK7	Neurological disorder	6B60	Discontinued in Phase 1	[47]
Opterone	DMPDJC8	Hormone deficiency	5A61.1	Discontinued in Phase 1	[26]
PF-06260414	DMSE3WP	Cachexia	MG20	Discontinued in Phase 1	[48]
LG-2293	DMNXKR2	Prostate cancer	2C82.0	Terminated	[50]
ZD-3980	DM91IPH	Prostate hyperplasia	GA90	Terminated	[51]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GLPG-0492	DMSW07R	Cachexia	MG20	Preclinical	[49]

25 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane	DMDJYHK	Discovery agent	N.A.	Investigative	[52]
11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol	DM9IHFY	Discovery agent	N.A.	Investigative	[53]
6,11-dihydrothiochromeno[4,3-b]indol-8-ol	DM0RB53	Discovery agent	N.A.	Investigative	[53]
Andromustine	DMHL0ID	Prostate cancer	2C82.0	Investigative	[54]
ARN34	DMMCFEX	Discovery agent	N.A.	Investigative	[55]
ASC-JMX2	DMYJ87C	Prostate hyperplasia	GA90	Investigative	[54]
ASC-JMZ1	DMT5LJN	Bladder cancer	2C94	Investigative	[54]
Boldenone	DM0EKO5	Discovery agent	N.A.	Investigative	[56]
Calusterone	DMBK2S8	Discovery agent	N.A.	Investigative	[57]
CH-4933468	DM1ZF3Y	Prostate cancer	2C82.0	Investigative	[54]
Delta1-dihydrotestosterone	DML6MVH	Discovery agent	N.A.	Investigative	[58]
DL-3	DME9ODX	Prostate cancer	2C82.0	Investigative	[54]
EPI-001	DMYWV81	Prostate cancer	2C82.0	Investigative	[59]
GTx-027	DM315VL	Solid tumour/cancer	2A00-2F9Z	Investigative	[60]
HYG-440	DM7XISZ	Dermatological disease	DA24.Y	Investigative	[61]
OXENDLONE	DM6RJOI	Discovery agent	N.A.	Investigative	[62]
Palodesangren C	DMKLVSO	Discovery agent	N.A.	Investigative	[62]
Palodesangren D	DMY6NRC	Discovery agent	N.A.	Investigative	[62]
Palodesangren E	DMUEK1N	Discovery agent	N.A.	Investigative	[62]
RU-59063	DM5D9UT	Discovery agent	N.A.	Investigative	[63]
SARMs	DMILBO9	Solid tumour/cancer	2A00-2F9Z	Investigative	[54]
SX-ARPC	DMEA36L	Prostate cancer	2C82.0	Investigative	[64]
Testetrol	DMQDVNZ	Hypogonadism	5A61.0	Investigative	[65]
[3H]methyltrienolone	DMTSGOW	Discovery agent	N.A.	Investigative	[56]
[3H]mibolerone	DM6HDKQ	Discovery agent	N.A.	Investigative	[63]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [4] Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [6] Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr J. 2004 Aug;51(4):425-34.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, ... Endocrinology. 1984 Jun;114(6):2100-6.
• [9] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [10] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [11] An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
• [12] Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
• [13] Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44.
• [14] Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
• [15] CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
• [16] The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4.
• [17] Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
• [18] Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
• [19] Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492-501.
• [20] Clinical pipeline report, company report or official report of Hinova Pharmaceuticals.
• [21] Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem. 1992 May 15;35(10):1663-70.
• [22] New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013 Feb;182(2):460-73.
• [23] Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4:e764.
• [24] Company report (Astrazeneca)
• [25] Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010 May 28;285(22):17054-64.
• [26] Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26.
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8638).
• [28] 2011 Pipeline of Adamis Pharmaceuticals.
• [29] Clinical pipeline report, company report or official report of Arvinas.
• [30] Targeting estrogen receptor alpha for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020 Nov 15;206:112689.
• [31] Clinical pipeline report, company report or official report of Arvinas
• [32] Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J Cancer. 2014 Jan 21;5(2):133-42.
• [33] Clinical pipeline report, company report or official report of Accutar Biotechnology
• [34] AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27.
• [35] ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health.
• [36] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039743)
• [37] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [38] Clinical pipeline report, company report or official report of ESSA Pharma.
• [39] Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008; 6: e010.
• [40] Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett. 2010 Dec 2;2(2):124-9.
• [41] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [42] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010426)
• [43] Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activity. J Neurobiol. 2003 Nov;57(2):163-71.
• [44] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028305)
• [45] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036899)
• [46] Influence of testosterone and a novel SARM on gene expression in whole blood of Macaca fascicularis. J Steroid Biochem Mol Biol. 2009 Apr;114(3-5):167-73.
• [47] Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 1998 May 1;55(9):1427-33.
• [48] Phase I clinical trail of PF-06260414 for treating cachexia. Pfizer Inc.
• [49] GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res. 2013 Jun;72:9-24.
• [50] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006840)
• [51] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009538)
• [52] Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. J Med Chem. 2006 Dec 14;49(25):7366-72.
• [53] Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3233-7.
• [54] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [55] Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol. 2004 Feb 12;214(1-2):175-87.
• [56] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [57] MR appearance of intra-abdominal metastatic melanoma. Magn Reson Imaging. 1992;10(4):705-8.
• [58] 17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol Lett. 2006 Aug 20;165(2):149-55.
• [59] EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
• [60] Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One. 2014 Jul 29;9(7):e103202.
• [61] Clinical pipeline report, company report or official report of Hygeia Therapeutics.
• [62] Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002.
• [63] Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile... J Med Chem. 2000 Aug 24;43(17):3344-7.
• [64] Clinical pipeline report, company report or official report of Progenics Pharmaceuticals Serometrix.
• [65] Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47-58.